Roman C. Sarott

This paper develops KAT-TCIPs to induce cell death in diffuse large B cell lymphoma by redirecting p300 and CBP to activate programmed cell death genes repressed by BCL6.

The paper demonstrates the use of a photoswitchable cannabinoid, azo-THC-3, to suppress seizures in a mouse model by local photoactivation in the hippocampus, avoiding systemic side effects.

This paper develops a small molecule, TRAP-1, that activates mutant p53 by forming a ternary complex with BRD4, leading to p53 target gene upregulation and inhibition of cancer cell growth.

This paper develops a TR-FRET-based assay to measure ligand binding kinetics for CB1R and CB2R, finding that D77 enables accurate determination of on- and off-rates for various agonists and antagonists.

This study develops a bivalent small molecule, EB-TCIP, that relocalizes EWS/FLI1 to induce BCL6 target genes, demonstrating a strategy to target fusion oncoproteins in Ewing sarcoma.

This study develops potent and selective CK1α molecular glue degraders through scaffold hopping and structure-activity relationship analysis of a glutarimide-based library.

The paper identifies CRBN-dependent WEE1 molecular glue degraders through combinatorial library screening and medicinal chemistry, providing structural insights into kinase selectivity.

This paper introduces LUX-MS, a light-triggered optoproteomic technology to map surfaceome receptor interactions and nanoscale organization, revealing insights into intercellular signaling and drug action.